HLA binding vaccine moieties and uses thereof

Patent metadata

Field	Value
Publication number	US-12358989-B2
Application number	US-202318469961-A
Country	US
Kind code	B2
Filing date	Sep 19, 2023
Priority date	Jun 21, 2016
Publication date	Jul 15, 2025
Grant date	Jul 15, 2025

Abstract

The present invention relates to an immunoglobulin derived single-chain fragment variable (scFv) that broadly binds HLA II molecules and uses thereof. In particular, targeting of an antigen to antigen presenting cells with the HLAII-specific targeting unit provided herein find use in enhancing immune responses after vaccination.

First claim

The invention claimed is:

1. A method of inducing an immune response in a subject, comprising:
administering a composition comprising:
a) a nucleic acid comprising:
(i) a sequence encoding an antibody, a scFv or a Fab fragment comprising light chain complementarity determining region (LCDR) 1 of SEQ ID NO:4; LCDR 2 of SEQ ID NO:5; and LCDR 3 of SEQ ID NO:6; and heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO:7; HCDR 2 of SEQ ID NO:8 and; HDCR 3 of SEQ ID NO:9; and
(ii) a sequence encoding at least one antigen; and

b) a pharmaceutically acceptable carrier;
to the subject under conditions such that an immune response is induced in said subject against the antigen.

2. The method of claim 1 , wherein the nucleic acid comprises a sequence encoding at least two distinct antigens.

3. The method of claim 1 , wherein said nucleic acid between said sequence encoding the antibody, scFv or Fab fragment and said sequence encoding the at least one antigen further comprises a sequence encoding a linker.

4. The method of claim 3 , wherein said linker comprises a dimerization unit comprising a hinge region from an immunoglobulin and an immunoglobulin constant region.

5. The method of claim 4 , wherein said dimerization unit is derived from a natural protein.

6. The method of claim 1 , wherein the at least one antigen is derived from a pathogenic microorganism.

7. The method of claim 6 , wherein said pathogenic microorganism is selected from the group consisting of orthomyxoviruses, paramyxoviruses, adenoviruses, rhinoviruses, coronaviruses, reoviruses, togaviruses, parvoviruses, poxviruses, enteroviruses, hepatitis viruses, herpesviruses, rotaviruses, Norwalk viruses, hantavirus, arenavirus, rhabdovirus, retroviruses, papovaviruses, polyomaviruses, picornaviruses, Dengue virus, Filoviruses, Hantavirus, Rift Valley virus, HHV-8, Human papillomavirus, Bovine leukemia virus, Influenza virus, Guanarito virus, Lassa virus, Measles virus, Rubella virus, Mumps virus, Chickenpox, Monkey pox, Epstein Bahr virus, Parvovirus B 19, Hantaan virus, Sin Nombre virus, Venezuelan equine encephalitis, Sabia virus, West Nile virus and Yellow Fever virus.

8. The method of claim 6 , wherein said pathogenic microorganism is selected from the group consisting of Influenza virus and Ebola virus.

9. The method of claim 1 , wherein the nucleic acid comprises a sequence that encodes the polypeptide of SEQ ID NO: 1.

10. The method of claim 1 , wherein the composition further comprises an adjuvant.

11. The method of claim 6 , wherein said method is for treating an infection by the pathogenic microorganism.

12. The method of claim 1 , wherein the antigen is influenza HA.

13. The method of claim 12 , wherein said method is for preventing an influenza virus infection.

14. The method of claim 1 , wherein the sequence (i) encodes a polypeptide of SEQ ID NO: 3.

Assignees

• Univ Oslo
• Nykode Therapeutics ASA

Inventors

• Grodeland Gunnveig
• Bogen Bjarne
• Fredriksen Agnete B

Classifications

• A61K39/00 Primary

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• C07K16/46

  Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00) · CPC title

• C07K16/34

  against blood group antigens · CPC title

• A61K39/39

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

• A61K39/12

  Viral antigens · CPC title